Latest updates for Abbv:ca
Fresh curated links around ABBV:CA are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Could AbbVie Inc. (ABBV)’s Post-Humira Transformation Drive the Next Phase of Growth?
- Aurora Cannabis Inc. 2027 Q1 - Results - Earnings Call Presentation
- Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Aurora Cannabis Inc. 2027 Q1 - Results - Earnings Call Presentation
Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)
Barrick Mining Corporation (ABX:CA) Q2 2026 Earnings Call Transcript
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?
The pharmaceutical company hopes that another big-time acquisition will pay off.
3 Reasons to Buy AbbVie Stock Like There's No Tomorrow
It looks like a great buy-and-hold option.
Broadcom: XPU Growth Trajectory Underestimated, Stock A Bargain
Better Dividend King to Buy Right Now: AbbVie or Johnson & Johnson?
Should You Buy AbbVie Stock Hand Over Fist Before July 31?
The recent rally could pave the way for "sell the news" volatility, but don't let this scare you out of a long-term position.
Advantage Energy: Strategic Direction Difference Becoming Apparent
How Will AbbVie's $10.9 Billion Acquisition of Apogee Impact Its Dividend?
There's no need to panic.
Abbott raises 2026 profit forecast on strength in diagnostics, heart devices
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
Bavarian Nordic A/S 2026 Q2 - Results - Earnings Call Presentation
Atea outlines peak annual U.S. net revenue potential in excess of $700M with focus on mid-2028 HCV launch
Ag Growth International Inc. (AFN:CA) Q2 2026 Earnings Call Transcript
The a2 Milk Company Limited 2026 Q4 - Results - Earnings Call Presentation
Corby Spirit and Wine Limited (CSW.A:CA) Q4 2026 Earnings Call Transcript
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.